EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review

Qian Liu, Lu Lv, Guanchao Pang, Pingli Wang

Current Oncology · 14.04.2026 · 33 (4) · 214

DOI: 10.3390/curroncol33040214 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, online erschienen am 14.04.2026. Verfasst von Qian Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Chin…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Afatinib, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR)-kinase domain duplication (KDD) represents an atypical mutation distinct from classical EGFR mutations in lung adenocarcinoma (LUAD). Although first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated clinical activity in EGFR-KDD, the mechanisms of acquired resistance in this setting remain poorly characterized. Herein, we present a LUAD patient with EGFR-KDD who achieved a sustained initial response to afatinib lasting 67 months before developing acquired resistance. Re-biopsy with next-generation sequencing (NGS) uncovered EGFR T790M, accompanied by EGFR amplification and EGFR M766T. The patient was switched to firmonertinib, with subsequent tumor regression. We reviewed published EGFR-KDD cases that had both acquired resistance to first- or second-generation EGFR-TKIs and corresponding repeat biopsy findings. Five of the eleven cases harbored EGFR T790M, yielding a prevalence of 45%, which is similar to that seen in classical EGFR mutations. This case suggests that EGFR T790M mediates acquired resistance to first- and second-generation EGFR-TKIs in EGFR-KDD, mirroring the resistance pattern observed in classical EGFR mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmAfatinibAdenocarcinoma of LungLung NeoplasmsProtein Kinase InhibitorsHumansErbB ReceptorsMutationMaleFemale

Stichwörter der Autor:innen

EGFR T790MEGFR-KDDacquired resistancelung adenocarcinomatyrosine kinase inhibitor

Substanzen

AfatinibErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.

Zitieren

APA

Liu, Q., Lv, L., Pang, G., & Wang, P. (2026). Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review. Current Oncology, 33(4), 214. https://doi.org/10.3390/curroncol33040214

Vancouver

Liu Q, Lv L, Pang G, Wang P. Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review. Current Oncology. 2026;33(4):214. doi:10.3390/curroncol33040214

BibTeX
@article{Liu2026,
  author = {Liu, Qian and Lv, Lu and Pang, Guanchao and Wang, Pingli},
  title = {Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {214},
  doi = {10.3390/curroncol33040214}
}
Kostenlos starten →